5 5.1. COMPARED CONSOLIDATED INCOME STATEMENTS € millions Notes 2021 2020 2019 Net sales 3.1 32,287.6 27,992.1 29,873.6 Cost of sales -8,433.3 - 7,532.3 -8,064.7 Gross profit 23,854.3 20,459.8 21,808.9 Research & Innovation expenses -1,028.7 -964.4 -985.3 Advertising and promotion expenses -10,591.0 - 8,647.9 -9,207.8 Selling, general and administrative expenses -6,074.2 - 5,638.5 -6,068.3 Operating profit 3.1 6,160.3 5,209.0 5,547.5 Other income and expenses 4 -432.0 -709.0 -436.5 Operational profit 5,728.3 4,500.0 5,111.0 Finance costs on gross debt -38.0 -79.2 -75.4 Finance income on cash and cash equivalents 18.5 19.8 28.7 Finance costs, net -19.4 -59.4 -46.7 Other financial income and expenses 9.4 -40.2 -36.5 -16.0 Sanofi dividends 378.3 372.4 363.0 Profit before tax and associates 6,046.9 4,776.5 5,411.4 Income tax 6 - 1,445.4 - 1,209.8 -1,657.2 Share of profit in associates 0.6 0.9 1.0 Net pr ofit 4,602.2 3,567.6 3,755.2 Attributable to: •owners of the company 4,597.1 3,563.4 3,750.0 •non-controlling interests 5.1 4.2 5.2 Earnings per share attributable to owners of the company (euros) 8.24 6.37 6.70 Diluted earnings per share attributable to owners of the company (euros) 8.21 6.34 6.66 Earnings per share attributable to owners of the company, excluding non-recurring items (euros) 11.4 8.86 7.33 7.78 Diluted earnings per share attributable to owners of the company, excluding non-recurring items (euros) 11.4 8.82 7.30 7.74 L ’ ORÉAL I UNIVERS AL REGISTRATION DOCUMENT 2021 285 2021 CONSOLIDATED FINANCIAL STATEMENTS Compared consolidated income statements